NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today it has entered into definitive agreements to sell common stock and warrants to selected institutional investors for aggregate gross proceeds of $1.3 million. The offering is made pursuant to the Form S-3 shelf registration statement that was filed by Pluristem with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on July 1, 2008. The offering is expected to close on or about May 11, 2009, subject to the satisfaction of customary closing conditions. Pluristem intends to use the net proceeds from the offering for its expected clinical trial, working capital and general corporate purposes.
